Key Points
- Insider sale: Francis Burrows sold 20,726 Kura Oncology shares for approximately $224,463, reducing his position by 32.87% to 42,327 shares.
- Stock and financial results: KURA opened at $10.76 and was down 0.9%; its latest quarterly loss of $0.77 per share was better than the $0.88 analyst estimate, while revenue reached $20.87 million.
- Analyst outlook: Wall Street maintains a “Moderate Buy” consensus, with an average price target of $25.40—well above the current share price—supported by 10 Buy ratings.
Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Francis Burrows sold 20,726 shares of the firm's stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $10.83, for a total value of $224,462.58. Following the transaction, the insider owned 42,327 shares of the company's stock, valued at approximately $458,401.41. The trade was a 32.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Kura Oncology Trading Down 0.9%
Shares of KURA stock opened at $10.76 on Friday. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $957.21 million, a price-to-earnings ratio of -3.19 and a beta of 0.44. Kura Oncology, Inc. has a 12-month low of $7.36 and a 12-month high of $13.90. The stock's 50-day moving average price is $11.22 and its 200-day moving average price is $10.13.
Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts' consensus estimates of ($0.88) by $0.11. The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. Equities research analysts predict that Kura Oncology, Inc. will post -3.25 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the company. Morgan Stanley set a $24.00 target price on Kura Oncology in a research report on Monday, August 24th. Citizens Jmp restated a "market outperform" rating and issued a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Raymond James Financial set a $24.00 price target on shares of Kura Oncology in a research note on Monday, August 24th. Wedbush increased their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the company an "outperform" rating in a research report on Thursday, August 13th. Finally, Wells Fargo & Company set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, June 4th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $25.40.
View Our Latest Research Report on Kura Oncology
Institutional Investors Weigh In On Kura Oncology
Several institutional investors have recently modified their holdings of KURA. IFP Advisors Inc lifted its stake in shares of Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company's stock valued at $25,000 after purchasing an additional 1,284 shares during the last quarter. Allworth Financial LP increased its position in shares of Kura Oncology by 59.9% during the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company's stock valued at $43,000 after purchasing an additional 1,553 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Kura Oncology by 49.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company's stock valued at $60,000 after purchasing an additional 1,888 shares during the last quarter. Pictet Asset Management Holding SA purchased a new stake in Kura Oncology during the 1st quarter valued at $96,000. Finally, E Fund Management Co. Ltd. purchased a new stake in Kura Oncology during the 2nd quarter valued at $132,000.
About Kura Oncology
(
Get Free Report)
Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company's research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.
Kura's leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
